Executives:
1. Robert J. Hariri, M.D., Ph.D. - Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer).
2. David C. Beers - Chief Financial Officer (Principal Financial and Accounting Officer).
3. Geoffrey Ling, M.D. - Director.
4. Dean C. Kehler - Director.
5. Diane Parks - Director.
6. Marc Mazur - Director.
7. Peter Diamandis - Director.
8. K. Harold Fletcher, Esq. - Attorney-in-fact.
Previous Information:
1. Robert Hariri (Founder, CEO, and Chairman) - Dr. Hariri is a successful entrepreneur, inventor, and physician-scientist who has pioneered the fields of cell therapy, immuno-oncology, and stem cell science.
2. Craig Dees (President and Chief Operating Officer) - Mr. Dees has over 35 years of experience in biotech, pharmaceuticals, and healthcare. He has previously served as the CEO of Provista Diagnostics, Inc., and Medistem, Inc.
3. Ram May-Ron (Chief Financial Officer) - Mr. May-Ron has over 20 years of experience in finance and operations for life science and technology companies. He has previously served as the CFO of Immunomedics, Inc.
4. Shila Pandey (Chief Medical Officer) - Dr. Pandey has over 20 years of experience in medicine and drug development. She has previously served as the Chief Medical Officer of Onconova Therapeutics, Inc.
Directors:
1. Robert Hariri (Founder, CEO, and Chairman) - Dr. Hariri is a successful entrepreneur, inventor, and physician-scientist who has pioneered the fields of cell therapy, immuno-oncology, and stem cell science.
2. J. Craig Venter (Founder and CEO of human longevity, Inc.) - Dr. Venter is a renowned scientist and entrepreneur who is known for his contributions to genomic research.
3. Stewart Hen (Managing Partner of Talon Opportunity Fund) - Mr. Hen has over 25 years of experience in private equity and venture capital.
4. Michael Hansel (Managing Director of Highline Capital Management) - Mr. Hansel has over 20 years of experience in healthcare investing.
5. Daniel Mendelson (Partner at Scopia Capital Management) - Mr. Mendelson has over 15 years of experience in healthcare investing.,
Celularity Inc currently has 120 employees.
News about Celularity Inc Key Personnel |
Celularity, a leading global biotechnology company specializing in advanced biomaterial products, has recently announced impressive net sales performance for the first quarter of 2024. The company has not only exceeded expectations but also strategized its 2024 selling, general, and administrative (SGandA) reductions, along with a manufacturing ramp. These developments mark a significant milestone for Celularity and point towards a promising future for the company in the field of innovative biomedical solutions.
Celularity s First Quarter Performance:
In its recent announcement, Celularity revealed its first-quarter net sales have been exceptional. The company has witnessed a significa...
|
Introduction
Celularity, a leading cell therapeutics company, has achieved a significant milestone with the receipt of Healthcare Common Procedure Coding System (HCPCS) Q Code approval from the U.S. Centers for Medicare and Medicaid Services (CMS). This approval establishes Biovance 3L, Celularity s advanced wound care product, as a nationally recognized treatment option for physicians in office settings. The Q Code approval marks a groundbreaking development in wound care treatment, further enhancing the accessibility and reimbursement capabilities for Biovance 3L. This article explores the implications of the Q Code approval and how it will revolutionize wound care treatment.
Unleashing Biovan...
|
